28th Feb 2007 17:23
AstraZeneca PLC28 February 2007 Dealing by DirectorsCompanies Act 1985 Sections 324/329 Transaction by Persons Discharging Managerial ResponsibilitiesDisclosure Rules DR 3.1.2R We hereby inform you that the interest of David R. Brennan, a Director of theCompany, in the shares of AstraZeneca PLC has changed as detailed below. MrBrennan has interests in both the Ordinary Shares and the American DepositaryShares (ADSs) of AstraZeneca PLC. One ADS equals one Ordinary Share. On 23 February 2007, Mr Brennan received an allocation of 12,014 Ordinary Sharesunder the previously disclosed arrangements relating to his annual bonus for2006 whereby he is required to defer a portion of the bonus earned into sharesfor a period of three years. The shares were allocated at a price of 2911 penceper share. Mr Brennan will become beneficially entitled to these shares on 23February 2010. On 23 February 2007, Mr Brennan received a scheduled distribution out of theAstraZeneca US Executive Deferral Plan, a unitised stock fund established in2000, in which Mr Brennan, in common with other participating US executives, isdeemed to have a notional interest in ADSs calculated by reference to the fundvalue and the closing price of AstraZeneca ADSs. Following this scheduleddistribution on 23 February 2007, Mr Brennan had a notional interest in 54,313ADSs within the AstraZeneca US Executive Deferral Plan by reference to theclosing price on 23 February 2006 of US$57.19. On 26 February 2007, Mr Brennan purchased, on his own account, additional ADSsto be held within the AstraZeneca US Executive Deferral Plan bringing hisnotional interest in ADSs held within the AstraZeneca US Executive Deferral Planas at 26 February 2007 to 62,192 ADSs based on that day's closing price ofUS$57.30. On 28 February 2007, Mr Brennan purchased, on his own account, 5,000 additionalADSs at a price of $56.34 per ADS to be held in a personal brokerage account. Immediately prior to the above transactions, Mr Brennan had an interest in98,553 Ordinary Shares and 170,538 AstraZeneca ADSs. As a result of thesetransactions, Mr Brennan's interest is now 110,567 Ordinary Shares and 160,297AstraZeneca ADSs, including the notional interest in ADSs in the AstraZeneca USExecutive Deferral Plan referred to above. This interest representsapproximately 0.018% of the Company's issued ordinary capital. G H R MuskerCompany Secretary28 February 2007 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Astrazeneca